Trial Profile
A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Avexitide (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Acronyms PREVENT
- Sponsors Eiger BioPharmaceuticals, Inc.
- 20 Jun 2022 The primary endpoint Incidence of treatment-emergent adverse events was removed, according to ClinicalTrials.gov record.
- 23 Feb 2021 Results published in the Eiger BioPharmaceuticals, Inc. Media Release.
- 23 Feb 2021 According to an Eiger BioPharmaceuticals, Inc. media release, positive results from the study were published in Journal of Clinical Endocrinology & Metabolism.